IL303686A - Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use - Google Patents

Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use

Info

Publication number
IL303686A
IL303686A IL303686A IL30368623A IL303686A IL 303686 A IL303686 A IL 303686A IL 303686 A IL303686 A IL 303686A IL 30368623 A IL30368623 A IL 30368623A IL 303686 A IL303686 A IL 303686A
Authority
IL
Israel
Prior art keywords
γglu
aib
isolated polypeptide
seq
spacer
Prior art date
Application number
IL303686A
Other languages
English (en)
Hebrew (he)
Original Assignee
I2O Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I2O Therapeutics Inc filed Critical I2O Therapeutics Inc
Publication of IL303686A publication Critical patent/IL303686A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL303686A 2020-12-17 2021-12-16 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use IL303686A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063126736P 2020-12-17 2020-12-17
PCT/US2021/063920 WO2022133148A1 (en) 2020-12-17 2021-12-16 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use

Publications (1)

Publication Number Publication Date
IL303686A true IL303686A (en) 2023-08-01

Family

ID=80123475

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303686A IL303686A (en) 2020-12-17 2021-12-16 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use

Country Status (12)

Country Link
US (2) US12084485B2 (https=)
EP (1) EP4263587A1 (https=)
JP (1) JP2024502740A (https=)
KR (1) KR20230156689A (https=)
CN (1) CN116917311A (https=)
AR (1) AR124395A1 (https=)
AU (1) AU2021400738A1 (https=)
CA (1) CA3202389A1 (https=)
IL (1) IL303686A (https=)
MX (1) MX2023007224A (https=)
TW (1) TW202237628A (https=)
WO (1) WO2022133148A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
AU2024218747A1 (en) * 2023-02-10 2025-08-28 Hangzhou Sciwind Biosciences Co., Ltd. Polypeptide and derivative thereof, composition, and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256056A1 (en) 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
JP6165168B2 (ja) * 2011-12-22 2017-07-19 ファイザー・インク 抗糖尿病化合物
UA116217C2 (uk) * 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
RU2760007C2 (ru) * 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
AU2017277594A1 (en) * 2016-06-09 2019-02-07 Medimmune Limited Protease-resistant mono-lipidated peptides
CN111333714A (zh) 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物

Also Published As

Publication number Publication date
JP2024502740A (ja) 2024-01-23
AR124395A1 (es) 2023-03-22
MX2023007224A (es) 2023-09-05
CA3202389A1 (en) 2022-06-23
WO2022133148A1 (en) 2022-06-23
US20250034225A1 (en) 2025-01-30
AU2021400738A1 (en) 2023-07-13
TW202237628A (zh) 2022-10-01
KR20230156689A (ko) 2023-11-14
US12084485B2 (en) 2024-09-10
US20230063420A1 (en) 2023-03-02
CN116917311A (zh) 2023-10-20
EP4263587A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
JP7636321B2 (ja) ヒトアミリンアナログペプチド及び使用方法
IL262802B2 (en) Glucagon receptor selective polypeptides and methods of using them
IL297375A (en) Controlled-release cnp agonists with low npr–c binding
US12122816B2 (en) Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
US20250034225A1 (en) Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use
WO2017200944A1 (en) Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
US20240228572A1 (en) Long acting glucagon receptor selective peptides and methods of use
CA3116023C (en) Human amylin analog polypeptides and methods of use
RU2839688C2 (ru) Полипептиды аналога амилина человека и способы их применения
EA052603B1 (ru) Селективные к рецептору глюкагона пептиды длительного действия и способы их применения